Abstract
Previously, we have established the experimental model using Sendai virus in mice for the screening of immunostimulants which were effective for the enhancement of nonspecific host resistance against viral infection (Ishihara 1985). By using this experimental model, we have reported that synthetic derivatives of N-acetylmuramyl-L-alanylD-isoglutamine (MDP), especially Nα-acetylmuramyl-L-alanyl-D-isoglutaminyl-Nε-stearoyl-L-lysine [MDP-Lys(L18)], chitin derivatives, polypeptides and dihydroheptaprenyl were potent immunostimulants for the potentiation of host resistance against bacterial and viral infections in experimental models (Iida 1987, 1989a, 1990; Ishihara 1985, 1987, 1989). More recently the efficacy of MDP-Lys(L18) was proved by clinical trials for the increase of the number of leukocytes and platelets of cancer patients who received chemotherapy and other conventional therapy (Tsubura 1988).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Adam A, Lederer E (1984) Muramyl peptides immunomodulators, sleep factors, and vitamins. Med Res Rev 4: 111–152
Azuma I (1987) Development of immunostimulants in Japan. In: Azuma I, Jollès G (eds) Immunostimulants: Now and Tomorrow, Japan Scientific Societies Press, Tokyo/Springer-Verlag, Berlin, p41
Azuma I (1989) Immunologic and biochemical properties of bacterial fractions and related compounds with special reference to BCG cell wall skeleton and Nocardia rubra cell wall skeleton. In: Yamamura Y, Azuma I (eds) Molecular and Cellular Networks for Cancer Therapy, Excerpta Medica, Tokyo, p 83
Chedid L, Parant M, Lefrancier P, Choay J, Lederer E (1977) Enhancement of nonspecific immunity to Klebsiella pneumoniae infection by a synthetic immunoadjuvant ( N-acetylmuramyl-L-alanyl-D-isoglutamine) and several analogs. Proc Natl Acad Sci USA 74: 2089–2093
Czuprynski CJ, Brown JF (1987) Recombinant murine interleukin-l8 enhancement of non-specific antibacterial resistance. Infect Immun 55: 2061–2065
Ellouz F, Adam A, Ciorbaru R, Lederer E (1974) Minimal structural requirement for adjuvant activity of bacterial peptidoglycan derivatives. Biochem Biophys Res Commun 59: 1317–1325
Ellouz F, Adam A, Ciorbaru R, Lederer E (1974) Minimal structural requirement for adjuvant activity of bacterial peptidoglycan derivatives. Biochem Biophys Res Commun 59: 1317–1325
Iida J, Saiki I, Ishihara C, Azuma I (1989a) Prophylactic activity against Sendal. virus infection and macrophage activation with lipophilic derivatives of N-acetylglucosaminylmuramyl tri-or tetrapeptides. Vaccine 7: 225–228
Iida J, Saiki I, Ishihara C, Azuma I (1989b) Protective activity of recombinant cytokines against Sendai virus and herpes simplex virus ( HSV) infections in mice. Vaccine 7: 229–233
Iida J, Une T, Ishihara C, Nishimura K, Mizukoshi N, Tokura S, Azuma I (1987) Stimulation of non-specific host resistance against Sendai virus and Escherichia coli infections by chitin derivatives in mice. Vaccine 5: 270–274
Ishihara C, Hamada N, Yamamoto K, Iida J, Azuma I, Yamamura Y (1985) Effect of muramyl dipeptide and its stearoyl derivatives on resistance to Sendai virus infection in mice. Vaccine 3: 370–374
Ishihara C, Iida J, Mizukoshi N, Yamamoto N, Yamamoto K, Kato K, Azuma I (1989) Effect of Na-acetylmuramyl-L-alanyl-D-isoglutaminylN-stearoyl-L-lysine on resistance to herpes simplex virus type-1 infection in cyclophosphamide-treated mice. Vaccine 7: 309–313
Ishihara C, Mizukoshi N, Iida J, Kato K, Yamamoto K, Azuma I (1987) Suppression of Sendai virus growth by treatment with Na -acetylmuramyl-L-alanyl-D-isoglutaminyl-N —stearoyl-L-lysine in mice. Vaccine 5: 295–301
Matsumoto K, Ogawa H, Kusama T, Nagase O, Sawaki N, Inage M, Kusumoto S, Shiba T, Azuma I (1981a) Stimulation of nonspecific resistance to infection induced by 6–0-acyl muramyl dipeptide analogs in mice. Infect Immun 32: 748–758
Matsumoto K, Ogawa H, Nagase O, Kusama T, Azuma I (1981b) Stimulation of nonspecific resistance to infection induced by muramyl dipeptides. Microbiol Immunol 25: 1047–1058
Matsumoto K, Osada Y, Une T, Otani T, Ogawa H, Azuma I (1987) Atniinfectious activity of the synthetic muramyl dipeptide analogue MDP-Lys(L18). In: Azuma I, Jollès G (eds) Immunostimulants: Now and Tomorrwo, Japan Scientific Societies Press, Tokyo/SpringerVerlag, Berlin, p 79
Matsumoto K, Otani T, Une T, Osada Y, Ogawa H, Azuma I (1983) Stimulation of nonspecific resistance to infection induced by muramyl dipeptide analogs substituted in the y-carboxy group and evaluation of Na-muramyl dipeptide-NE-stearoyllysine. Infect Immun 39: 10291040
Matsumoto M, Matsubara S, Matsuno T, Tamura M, Hattori K, Nomura H, Ono M, Yokota T (1987) Protective effect of human granulocyte colony-stimulating factor on microbial infection in neutropenic mice. Infect Immun 55: 2715–2720
Moroi R, Yamazaki K, Hirota T, Watanabe S, Kataoka K, Ichinose M (1988) Physico-chemical properties of muroctasin. Arzneim-Forsch/ Drug Res 38 (II): 953–959
Otani T, Une T, Osada Y (1988) Stimulation of non-specific resistance to infection by muroctasin. Arzneim-Forsch/Drug Res 38 (II): 969–976
Ozaki Y, Ohashi T, Minami A, Nakamura S (1987) Enhanced resistance of mice to bacterial infection induced by recombinant human interleukin-lß. Infect Immun 55: 1436–1440
Roberts NJ, Jr, Prill AH, Mann TN (1986) Interleukin 1 and interleukin 1 inhibitor production by human macrophages exposed tp influenza virus or respiratory synctial virus. Respiratory synctial virus is a potent inducer of inhibitor activity. J Exp Med 163: 511–519
Saiki I, Saito S, Fujita C, Ishida H, Iida J, Murata J, Hasegawa A, Azuma I (1988) Induction of tumorcidal macrophages and production of cytokines by synthetic muramyl dipeptide analogs. Vaccine 6: 238–244
Tsubura E, Nomura T, Niitani H, Osamura S, Okawa T, Tanaka M, Ota K, Nishikawa H, Masaoka T, Fukuoka M, Horiuchi A, Furuse K, Ito M, Nagai K, Ogura T, Kozuru M, Hara N, Hara K, Ichimura M, Takatsuki K (1988) Leukopenia associated with anticancer treatment. ArzneimForsch/Drug Res 38 (II) Nr 7a: 1070–1074
Watanabe K, Saiki I, Uraki Y, Tokura S, Azuma I (1990) 6–0-Carboxymethyl-chitin ( CM-chitin) as a drug carrier. Chem Pharm Bull 38: 506–509
Werner GH (1987) Immunostimulants: The western Scene. In: Azuma I, Jollès G (eds) Immunostimulants: Now and Tomorrow, Japan Scientific Societies Press, Tokyo/Springer-Verlag, Berlin, p 3
Yamaguchi F, Akasaki M, Tsukada W (1988) Induction of colony-stimulating factor and stimulation of stem cell proliferation by injection of muroctasin. Arzneim-Forsch/Drug Res 38 (II): 980–983
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Azuma, I., Ishihara, C., Iida, J., Yamamura, Y. (1990). Protective Activity of MDP-Lys (L-18) and Recombinant Cytokines Against Sendai Virus and Herpes Simplex Virus (HSV) Infections in Mice. In: Masihi, K.N., Lange, W. (eds) Immunotherapeutic Prospects of Infectious Diseases. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-76120-1_33
Download citation
DOI: https://doi.org/10.1007/978-3-642-76120-1_33
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-76122-5
Online ISBN: 978-3-642-76120-1
eBook Packages: Springer Book Archive